Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.āāā⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$3.83
Price+18.42%
$0.60
$327.383m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$482k
-
1y CAGR-
3y CAGR-
5y CAGR-$99.786m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.56
-
1y CAGR-
3y CAGR-
5y CAGR$119.854m
$149.988m
Assets$30.134m
Liabilities$4.614m
Debt3.1%
-
Debt to EBITDA-$92.591m
-
1y CAGR-
3y CAGR-
5y CAGR